

# Performance of BioFire Array or QuickVue Influenza A+B Test versus a validation qPCR assay for detection of influenza A during a volunteer A/California/2009/H1N1 challenge study

David R. McIlwain (✉ [mcilwain@stanford.edu](mailto:mcilwain@stanford.edu))

Stanford University School of Medicine <https://orcid.org/0000-0002-2537-0273>

Han Chen

Stanford University School of Medicine

Maria Apkarian

WCCT Global

Melton Affrime

WCCT Global

Bonnie Bock

WCCT Global

Kenneth Kim

ARK Clinical Research

Nilanjan Mukherjee

Stanford University School of Medicine

Garry P. Nolan

Stanford University School of Medicine

Monica M. McNeal

Cincinnati Children's Hospital Medical Center

---

## Research

**Keywords:** Influenza; H1N1; volunteer influenza challenge study; Biofire Film Array; rapid influenza diagnostic test; RIDT; qPCR

**Posted Date:** April 23rd, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-22980/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

# Abstract

**Background:** Influenza places a significant burden on global health and economics. Individual case management and public health efforts to mitigate the spread of influenza are both strongly impacted by our ability to accurately and efficiently detect influenza viruses in clinical samples. Therefore, it is important to understand the performance characteristics of available assays to detect influenza in a variety of settings. We provide the first report of relative performance between two products marketed to streamline detection of influenza virus in the context of a highly controlled volunteer influenza challenge study.

**Methods:** Nasopharyngeal swab samples were collected during a controlled A/California/2009/H1N1 influenza challenge study and analyzed using for detection of virus shedding using a validated qRT-PCR (qPCR) assay, a sample-to-answer qRT-PCR device (BioMerieux BioFire FilmArray RP), and an immunoassay based rapid test kit (Quidel QuickVue Influenza A+B Test).

**Results:** Relative to qPCR, the sensitivity and specificity of the BioFire assay was 72.1% (63.7%-79.5%, 95% Confidence Interval (CI)) and 93.5% (89.3%-96.4%, 95% CI) respectively. For the QuickVue rapid test the sensitivity was 8.5% (4.8%-13.7%, 95% CI) and specificity was 99.2% (95.6%-100%, 95% CI).

**Conclusion:** Relative to qPCR, the BioFire assay had superior performance compared to rapid test in the context of a controlled influenza challenge study.

## Background

Influenza remains a major global health concern with significant morbidity and mortality from seasonal infections and poses the potential for catastrophic pandemics (1). In addition to the human cost, influenza infection also results in a tremendous economic burden with more than 20 million days of lost annual productivity and an estimated \$11.2 billion in annual direct or indirect costs in the United States alone (2).

Distinguishing influenza infection from other acute respiratory conditions based on symptoms alone is difficult (3), but timely and accurate detection of influenza infection is a key component of both global disease surveillance monitoring, individual clinical case management, and clinical studies. A gold-standard for definitive diagnosis of influenza infections is a quantitative real-time polymerase chain reaction (qPCR) assay where the copies of viral nucleic acid in clinical samples are quantified and compared to a standard curve produced using the same strain (4, 5). However, standard qPCR approaches are time consuming and require trained operators in a laboratory setting (5). Other options for more rapid diagnosis are designed to overcome some of these limitations, including point-of-care colorimetric immunoassay based rapid influenza tests, and sample-to-answer PCR-based systems (6). However, performance characteristics of each assay should always be a major consideration when choosing an influenza test.

Controlled human infection studies where healthy volunteers are challenged with influenza virus are important tools for evaluation of novel influenza therapeutics (7–9). Such studies also provide a rare opportunity to examine the performance characteristics of influenza diagnostics in a highly disciplined setting. While multiple studies have reported the relative performance of different influenza detection methods (10), such assays are rarely (if ever) compared using clinical samples obtained from a cohort of individuals all exposed to a genetically identical virus. Samples obtained in a volunteer A/California/2009/H1N1 influenza challenge study were separately compared to test outcomes of a validated qPCR assay versus a sample-to-answer qPCR device (BioMerieux BioFire FilmArray RP) and an immunoassay based rapid test kit (Quidel QuickVue Influenza A + B Test).

## Methods

### Influenza challenge study design and sample collection

During a volunteer influenza challenge study (ClinicalTrials.gov Identifier: NCT02918006) (11), 143 volunteers were challenged intranasally with approximately  $5.50 \times 10^5$  to  $3.5 \times 10^6$  TCID<sub>50</sub> units of A/California/2009/H1N1 virus. Nasopharyngeal (NP) swabs (Quidel, San Diego, CA) were collected up to twice daily by inserting the swab into the nasopharynx and turning prior to placement in a supplied tube containing universal virus transport medium. NP swab specimens were used for detection of virus shedding by a validated qPCR assay (qPCR) throughout the study. Starting on day 4 post virus challenge, duplicate NP swabs were collected and used for analysis with either the BioMerieux BioFire FilmArray RP (BioFire) or Quidel QuickVue Influenza A + B Test (rapid test) in addition to the qPCR assay.

### Quantitative Real-Time PCR (qPCR) assay and qualification

A real time PCR (qPCR) method was adapted from a method developed at the US Centers for Disease Control and Prevention (CDC) and validated at the Laboratory for Specialized Clinical Studies at Cincinnati Children's Hospital Medical center. The assay detected and quantified shedding of Influenza A/California/04/2009 H1N1 virus in clinical samples. Nucleic acid extraction of 140 µL of the NP swab samples was carried out by use of the Qiagen QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany). Primers and probes (Biosearch Technologies, Inc, Novato, CA) targeting the HA gene of the pandemic (pdmH1) influenza A (H1N1) 2009 virus were used (**Table S1**). To evaluate the quality of the NP swab samples, a separate PCR reaction was performed to detect the Human RNPase P gene. Detection of this gene confirms that the swab sample is of sufficient quality that cell associated virus can be detected and quantified and acts as an internal control for any possible PCR inhibitors in the swab sample. A one-step quantitative RT-probe Hydrolysis kit, Ambion AgPath-ID™ One-Step kit (Thermo Fisher, Waltham, MA) was used in the PCR reaction following manufacturer's instructions. Final concentration of primers was 0.8 µM and 0.2 µM for the probe. 5 µL of the extracted material was used in each reaction. PCR conditions using an Applied Biosystems ABI 7500 PCR system (Thermo Fisher, Waltham, MA) were as

follows: 50.0 °C for 30 minutes; 95.0 °C for 10 minutes; 45 cycles of 95 °C, 15 seconds followed by 55 °C for 34 seconds.

To develop a standard curve for quantitation, the HA gene sequence was obtained from GenBank (KU933485.1) for A/California/07/2009. A forward primer at positions 1–25 (ATGAAGGCAATACTAGTAGTTCTGC) with a 5' T7 promoter and a reverse primer at positions 1702 – 1673 (TTAAATACATATTCTACTGTAGAGACCC) were used to generate a transcript of 1702 base pairs in a one-step RT PCR reaction. The product was run on a 1% gel and the band was purified with the Zymoclean Gel DNA Recovery Kit (Zymo Research, Irvine, CA). A Megascript T7 transcription kit (Thermo Fisher, Waltham, MA) was used to generate an RNA transcript. The transcript was cleaned up using the Qiagen RNeasy Mini Kit (Qiagen, Hilden, Germany), run on a 1% agarose gel to confirm the size, and then quantified by multiple readings on a Nanodrop. The concentration and copy number were calculated from the OD readings. Standard curves were generated by freshly diluting transcripts tenfold from  $4.0 \times 10^6$  to 4.0 copies/ $\mu\text{L}$  ( $2.0 \times 10^7$  to 20.0 copies/reaction) prior to each run. Standard curves were shown to have an average efficiency of 100% based on the slope of the curves. A positive control of extracted A/California/04/2009 H1N1 virus was run in the reaction over 20 times by two technicians over a 5-week period to obtain data to set an acceptance range based on 2 standard deviations of the average quantity obtained in the assay.

To confirm specificity towards A/California H1N1, eight different influenza A and B viruses (**Table S2**) were tested in the assay. Only A/California H1N1 specific isolates were detected in the assay. Additionally, to demonstrate specificity of the primers and probe, the PCR product of the positive virus control was run on a 2% agarose gel and assessed for a band at 177 bp to confirm that only the targeted portion of the gene was amplified (**Figure S1**). Intra- assay precision and intermediate precision was determined to have a coefficient of variance (CV) of 11% and 25%, respectively.

The limit of detection (LOD) for the assay was determined from running the standard reference in two-fold dilutions surrounding the lower end of the standard curve in replicates of 20. The LOD was then calculated as the concentration where 95% of the reference standard dilutions gave a positive response ( $C_t \leq 40$ ). The LOD was calculated to be 16 copies/reaction. For purposes of comparison with BioFire or rapid test, qPCR samples above the LOD were considered positive, samples below the LOD were considered to be negative.

## BioFire FilmArray

NP swab samples were loaded into the Biofire FilmArray respiratory panel cassette according to manufacturer's instructions and analyzed using the BioFire FilmArray Multiplex PCR System (BioMerieux, Marcy-l'Étoile, France). This device uses a fully automated procedure for nucleic acid purification, amplification, multiplexed PCR and melting analysis, and generates a report with binary outcomes for various respiratory pathogens. Samples positive for influenza A in this report were considered positive, all other samples were considered negative. Samples with positive for any other targets were excluded from analysis.

# Rapid Influenza Test

NP swabs samples were applied to the QuickVue Influenza A + B Test (Quidel, San Diego, CA) using manufacturer's instructions. Colorimetric tests were read by eye to determine positive or negative results as per protocol in the test kit insert.

## Statistical Analysis

Sensitivity (true positive rate) was calculated as the ratio of true positive results divided by the sum of true positive and false negative results  $[(\text{true positive})/(\text{true positive} + \text{false negative})]$ . The specificity (true negative rate) was calculated by dividing the number of true negative results by the total number of true negative plus false positive results  $[(\text{true negative})/(\text{true negative} + \text{false positive})]$ . The positive and negative predictive values were calculated as true positive divided by all positive results and true negative divided by all negative results, respectively. The confidence interval was calculated using the epiR package (12).

## Results

During a recent volunteer influenza challenge study, 143 healthy volunteers were challenged intranasally with A/California/2009/H1N1 virus. Nasopharyngeal (NP) swabs were routinely collected and tested for presence of influenza virus as part of the clinical conduct of this study. Duplicate NP swabs were collected and used for analysis with either the BioMerieux BioFire FilmArray RP (BioFire) or Quidel QuickVue Influenza A + B Test (rapid test) in addition to the validated qPCR assay, thus providing an opportunity to compare the relative performance of these tests.

To facilitate the analysis described here, the gold-standard qPCR assay was considered to be diagnostically accurate for detection of influenza A virus in all samples. All values above the LOD by qPCR were recorded as positive, and all samples below the LOD were recorded as negative.

A total of 351 duplicate NP swab samples were tested by both BioFire and qPCR. Of the 136 virus positive samples, BioFire correctly identified 98 samples as positive for influenza A (true positive) and 38 samples as negative for virus (false negative). The BioFire assay also accurately classified 201 samples as negative for virus (true negative) while incorrectly classifying 14 samples as positive (false positive) (Table 1, Fig. 1). As such, the sensitivity and specificity of the BioFire assay relative to qPCR was 72.1% (63.7%-79.4%, 95% Confidence Interval (CI)) and 93.5% (89.3%-96.4%, 95% CI), respectively (Table 2).

A similar analysis was completed for 299 duplicate NP swab samples that were tested by both qPCR and rapid test. Of 176 qPCR positive samples, rapid test recorded 15 true positives and 161 false negatives. Of the 123 qPCR negative samples, rapid test identified 122 true negatives and one false positive (Table 1, Fig. 2). This resulted in a sensitivity of 8.5% (4.8%-13.7%, 95% CI) and specificity of 99.2% (95.6%-100%, 95% CI) for rapid test relative to qPCR (Table 2).

Table 1  
Results for paired tests performed by BioFire and qPCR or rapid test and qPCR.

Diagnostic Test		qPCR	
		qPCR Positive	qPCR Negative
<b>BioFire</b> (n = 351)	Positive	98	14
	Negative	38	201
<b>Rapid Test</b> (n = 299)	Positive	15	1
	Negative	161	122

Table 2  
Sensitivity and specificity of BioFire and rapid test vs. qPCR.

Diagnostic Test	Specificity (TPR)			Sensitivity (TNR)		
	TP/(TP + FN)	%	95% CI	TN/(TN + FP)	%	95% CI
<b>BioFire</b>	98/136	72.1	63.7–79.4	201/215	93.5	89.3–96.4
<b>Rapid Test</b>	15/176	8.5	4.8–13.7	122/123	99.2	95.6–100

Sensitivity %, or true positive rate (TPR), was calculated as number of true positive (TP) divided by the sum of TP and false negative (FN). Specificity %, or true negative rate (TNR), was calculated as the number of true negatives (TN) divided by the sum of TN and false positives. 95% confidence interval (CI) calculated using the epiR package in R.

## Discussion

Rapid and simplified methods for influenza virus detection are important tools, but it is important to understand how these tests compare to other assays in different settings. Here the performance of BioFire, a simplified sample-to-answer qPCR-based detection method, and QuickVue Influenza A + B Test rapid test, a colorimetric immunoassay, were assessed by comparing their diagnostic results to a validated qPCR assay using paired samples from a A/California/2009/H1N1 volunteer challenge study. Based on this analysis, BioFire was largely consistent with qPCR, while the rapid test suffered from a large degree of false negatives.

BioFire is an arrayed multiplexed qPCR-based device delivering binary results (positive or negative) for targets included in its assay cassettes. Although BioFire had a high specificity of 93.5%, sensitivity of BioFire was lower at 72.1%. This lower sensitivity may reflect a higher LOD by the BioFire assay for the A/California/2009/H1N1 influenza challenge strain compared to qPCR in the context of this study. A higher LOD could result from differences in sample prep, primer sets, instrumentation, or programmed reporting threshold. Our calculated sensitivity of 72.1% for BioFire was only slightly lower than the 73–

89% sensitivity range reported in other studies (13–15). Taken together, while such assays are simpler to use and offer a quicker turnaround compared to standard qPCR, this may come at the expense of slightly decreased sensitivity.

Rapid influenza diagnostic tests are well known to have decreased sensitivity compared to qPCR (16). While some studies have reported sensitivities as high as 63–71% (17, 18), others report much lower values in the range of 26–33% (19, 20). In our analysis the rapid test sensitivity was very low, at only 8.5% relative to qPCR. This wide range of sensitivities reported across studies may be attributed to differences in virus strain or magnitude of antigen load, at least in part, by the day post-infection in which samples are collected. Additionally, as a colorimetric test, the qualitative results are susceptible to greater variation due to biases in operator readings compared to the quantitative driven results of qPCR and BioFire. Nevertheless, the specificity of the rapid test is very high. Our study found a specificity of 99.2% for this test, in line with other reports of 96–100% specificity (17–20). Therefore, despite poor sensitivity, when present, a positive rapid test is a strong indicator that a sample will also be positive by qPCR.

For operational reasons, this study was limited to examining samples starting at 4 days post-viral challenge, corresponding to approximately three days post-symptom onset in challenge models (7). In other studies examining performance of the influenza detection assays during community acquired infection (13, 17–20), NP samples were collected immediately when patients met a set of subjective symptom criteria. Symptom-based selection in those studies may bias for individuals with higher magnitudes of viral titer and antigen load compared to a controlled challenge study in which all study participants are assessed. These differences may explain the reduced overall performance of the rapid test in this study compared to prior studies. Nevertheless, the data reported here is important for our broader understanding of the performance of this diagnostic tool, especially for those considering their use in future influenza challenge studies. If available from future influenza challenge studies, an examination of samples taken over the entire course of virus shedding period, including from earlier timepoints post-inoculation would be worthwhile to determine the relationship between day post-infection, viral load, and performance of both rapid tests and sample-to-answer molecular tests for influenza A.

## Conclusion

In summary, we have compared performance of two simplified influenza A detection methods to a validated qPCR assay in a controlled A/California/2009/H1N1 challenge study. In this setting, BioFire closely reflected virus shedding detected by qPCR, while the rapid test did not. While not without limitations, integration of sample-to-answer influenza tests such as BioFire into environments where standard qPCR assays are impractical stands to greatly improve detection of influenza over antigen-based rapid tests alone.

## Abbreviations

CDC: US Centers for Disease Control and Prevention; CI: Confidence interval; CV: Coefficient of variance; LOD: Limit of detection; NP: Nasopharyngeal; pdmH1: Pandemic influenza A (H1N1) 2009; qPCR: Quantitative real-time polymerase chain reaction

## **Declarations**

### **ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

Samples were obtained from volunteers who provided written informed consent in accordance to Stanford University Administrative Panel on Human Subject Research's Institutional Review Board (IRB) protocols. Samples were de-identified from donors following the guidelines of Stanford University's Environmental Health and Safety Biosafety program.

### **CONSENT FOR PUBLICATION**

Not applicable.

### **AVAILABILITY OF DATA AND MATERIALS**

Information about the intranasal influenza A/California/2009/H1N1 challenge can be found at ClinicalTrials.gov Identifier: NCT02918006. Other datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### **COMPETING INTERESTS**

The authors declare that they have no competing interests.

### **FUNDING**

This work was supported by the Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response and by the US National Institutes of Health grant 5U19AI100627-07. D.R.M was supported by a Canadian Institutes of Health Research post-PhD Fellowship.

### **AUTHORS' CONTRIBUTIONS**

DRM, MMM, KK, GPN, BB, MAp, and MAf. designed the study. MMM, BB, MAp, generated data. HC, DRM, NM analyzed data. DRM, HC, MMM wrote the manuscript.

### **ACKNOWLEDGEMENTS**

We would like to thank Dave Liebowitz, Sean Tucker, and the team at Vaxart, Inc. for providing samples needed to perform the analysis.

# References

1. Webster RG, Govorkova EA. Continuing challenges in influenza. *Ann N Y Acad Sci*. 2014;1323(1):115–39. Available from: <https://doi.org/10.1111/nyas.12462>
2. Putri WCWS, Muscatello DJ, Stockwell MS, Newall AT. Economic burden of seasonal influenza in the United States. *Vaccine*. 2018;36(27):3960–6. Available from: <https://doi.org/10.1016/j.vaccine.2018.05.057>
3. Van Elden LJR, Van Essen GA, Boucher CAB, Van Loon AM, Nijhuis M, Schipper P, et al. Clinical diagnosis of influenza virus infection: Evaluation of diagnostic tools in general practice. *Br J Gen Pract*. 2001;51(469):630–4.
4. Mackay IM, Arden KE, Nitsche A. Real-time PCR in virology. *Nucleic Acids Res*. 2002;30(6):1292–305. Available from: <https://doi.org/10.1093/nar/30.6.1292>
5. Templeton KE, Scheltinga SA, Beersma MFC, Kroes ACM, Claas ECJ. Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by Influenza A and Influenza B Viruses, Respiratory Syncytical Virus, and parainfluenza Viruses 1, 2, 3, and 4. *J Clin Microbiol*. 2004;42(4):1564–9. Available from: <https://doi.org/10.1128/jcm.42.4.1564-1569.2004>
6. Sampath R, Hall TA, Massire C, Li F, Blyn LB, Eshoo MW, et al. Rapid identification of emerging infectious agents using PCR and electrospray ionization mass spectrometry. *Ann N Y Acad Sci*. 2007 Apr 1;1102(1):109–20. Available from: <https://doi.org/10.1196/annals.1408.008>
7. Balasingam S, Wilder-Smith A. Randomized controlled trials for influenza drugs and vaccines: A review of controlled human infection studies. *Int J Infect Dis*. 2016;49(2016):18–29. Available from: <https://doi.org/10.1016/j.ijid.2016.05.013>
8. Carrat F, Vergu E, Ferguson NM, Lemaître M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: A review of volunteer challenge studies. *Am J Epidemiol*. 2008;167(7):775–85. Available from: <https://doi.org/10.1093/aje/kwm375>
9. Sherman AC, Mehta A, Dickert NW, Anderson EJ, Roupheal N. The future of flu: A review of the human challenge model and systems biology for advancement of influenza vaccinology. *Front Cell Infect Microbiol*. 2019;9(Apr):1–9. Available from: <https://doi.org/10.3389/fcimb.2019.00107>
10. Yoon J, Yun SG, Nam J, Choi SH, Lim CS. The use of saliva specimens for detection of influenza A and B viruses by rapid influenza diagnostic tests. *J Virol Methods*. 2017;243:15–9. Available from: <https://doi.org/10.1016/j.jviromet.2017.01.013>
11. Liebowitz D, Gottlieb K, Kolhatkar NS, Garg SJ, Asher JM, Nazareno J, et al. Articles Efficacy , immunogenicity , and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study. *Lancet Infect Dis*. 2020;3099(19):1–10. Available from: [http://dx.doi.org/10.1016/S1473-3099\(19\)30584-5](http://dx.doi.org/10.1016/S1473-3099(19)30584-5)
12. Stevenson M, Nunes T, Heuer C, Marshall J, Sanchez J, Thorn- R, et al. Package ‘epiR.’ 2019; Available from: <https://cran.r-project.org/web/packages/epiR/epiR.pdf>

13. Chan M, Koo SH, Jiang B, Lim PQ, Tan TY. Comparison of the Biofire FilmArray Respiratory Panel, Seegene AnyplexII RV16, and Argene for the detection of respiratory viruses. *J Clin Virol*. 2018;106(July):13–7. Available from: <https://doi.org/10.1016/j.jcv.2018.07.002>
14. Popowitch EB, O'Neill SS, Miller MB. Comparison of the biofire filmarray RP, Genmark eSensor RVP, Luminex xTAG RVPv1, and Luminex xTAG RVP fast multiplex assays for detection of respiratory viruses. *J Clin Microbiol*. 2013;51(5):1528–33. Available from: <https://doi.org/10.1128/JCM.03368-12>
15. Ruggiero P, McMillen T, Tang YW, Babady NE. Evaluation of the BioFire FilmArray Respiratory Panel and the GenMark eSensor Respiratory Viral Panel on Lower Respiratory Tract Specimens. *J Clin Microbiol*. 2014;52(1):288–90. Available from: <https://doi.org/10.1128/JCM.02787-13>
16. Centers for Disease Control and Prevention. Guidance for Clinicians on the Use of Rapid Influenza Diagnostic Tests. CDC. 2013;(1):1. Available from: [http://www.cdc.gov/flu/professionals/diagnosis/clinician\\_guidance\\_ridt.htm](http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm)
17. Grijalva CG, Poehling KA, Edwards KM, Weinberg GA, Staat MA, Iwane MK, et al. Accuracy and interpretation of rapid influenza tests in children. *Pediatrics*. 2007;119(1).
18. Hurt AC, Alexander R, Hibbert J, Deed N, Barr IG. Performance of six influenza rapid tests in detecting human influenza in clinical specimens. *J Clin Virol*. 2007;39(2):132–5. Available from: <https://doi.org/10.1016/j.jcv.2007.03.002>
19. Stein J, Louie J, Flanders S, Maselli J, Hacker JK, Drew WL, et al. Performance characteristics of clinical diagnosis, a clinical decision rule, and a rapid influenza test in the detection of influenza infection in a community sample of adults. *Ann Emerg Med*. 2005;46(5):412–9. Available from: <https://doi.org/10.1016/j.annemergmed.2005.05.020>
20. Uyeki TM, Prasad R, Vukotich C, Stebbins S, Rinaldo CR, Ferng Y, et al. Low Sensitivity of Rapid Diagnostic Test for Influenza. *Clin Infect Dis*. 2009;48(9):e89–92. Available from: <https://doi.org/10.1086/597828>

## Additional Files

***Additional File 1 (.xlsx):*** Table S1

**Table S1: qPCR Primers and probes used to target the HA gene of the pandemic (pdmH1) influenza A (H1N1) 2009 virus**


***Additional File 2 (.xlsx):*** Table S2

**Table S2: Confirmation of Specificity of qPCR test for A/California H1N1.** Eight different influenza A and B strains were used to test the specificity of the qPCR assay. Ct values confirm assay is specific for A/California H1N1 viruses.

***Additional File 3 (.pdf):*** Figure S1


**Figure S1: Confirmatory PCR product from positive virus control.** An expected single band of ~177bp amplified by PCR demonstrates specificity of the primers to amplify the targeted region of the HA gene.

## Figures



**Figure 1**

Venn diagram of BioFire performance vs qPCR. Number of samples positive by qPCR (blue), positive by BioFire (green), or positive by both qPCR and BioFire (yellow). Samples negative for both qPCR and BioFire (grey). Size of circles is proportional to n.



**Figure 2**

Venn diagram of rapid test performance vs. qPCR. Number of samples positive by qPCR (blue), positive by rapid test (green), or positive by both qPCR and rapid test (yellow). Samples negative for both qPCR and rapid test (grey). Size of circles is proportional to n.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AdditionalFile1TableS1.xlsx](#)
- [AdditionalFile2TableS2.xlsx](#)
- [AdditionalFile3FigureS1.pdf](#)